Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial.

MLA

Einem, Jobst Christian, et al. “Treatment of Advanced Gastrointestinal Cancer with Genetically Modified Autologous Mesenchymal Stem Cells: Results from the Phase 1/2 TREAT‐ME‐1 Trial.” International Journal of Cancer, vol. 145, no. 6, Sept. 2019, pp. 1538–46. EBSCOhost, https://doi.org/10.1002/ijc.32230.

APA

Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D., Salat, C., Stoetzer, O., Nelson, P. J., Michl, M., Modest, D. P., Holch, J. W., Angele, M., Bruns, C., Niess, H., & Heinemann, V. (2019). Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial. International Journal of Cancer, 145(6), 1538–1546. https://doi.org/10.1002/ijc.32230

Chicago

Einem, Jobst Christian, Christine Guenther, Hans‐Dieter Volk, Gerald Grütz, Daniela Hirsch, Christoph Salat, Oliver Stoetzer, et al. 2019. “Treatment of Advanced Gastrointestinal Cancer with Genetically Modified Autologous Mesenchymal Stem Cells: Results from the Phase 1/2 TREAT‐ME‐1 Trial.” International Journal of Cancer 145 (6): 1538–46. doi:10.1002/ijc.32230.